Efforts to help build Africa’s vaccine manufacturing sector received a boost recently with new deals and expanded partnerships.
BioGeneric Pharma in Egypt and Afrigen Biologics in South Africa expanded their partnership to develop specific mRNA vaccines. The two have been working together as part of efforts to build the African continent’s vaccine manufacturing capacities and capabilities to produce mRNA vaccines.
BioGeneric Pharma is one of the recipients of the mRNA technology transfer program established by the World Health Organization and the Medicines Patent Pool to build the capacity of low- and middle-income countries to produce mRNA vaccines. Afrigen serves as the host of this program and has provided training programs on developing mRNA vaccines to several manufacturers, including BioGeneric Pharma.
About the author
Jenny Lei Ravelo@JennyLeiRavelo
Jenny Lei Ravelo is a Devex Senior Reporter based in Manila. She covers global health, with a particular focus on the World Health Organization, and other development and humanitarian aid trends in Asia Pacific. Prior to Devex, she wrote for ABS-CBN, one of the largest broadcasting networks in the Philippines, and was a copy editor for various international scientific journals. She received her journalism degree from the University of Santo Tomas.
